KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Theorem Clinical Research, a leading global contract research organization (CRO) that optimizes trial conduct, has selected Scott P. Treiber, Ph.D., MBA, to spearhead biopharmaceutical development as executive vice president and general manager.
“Scott is an extraordinary individual with valuable experience in clinical development, medical affairs, data management and other areas of biopharmaceutical development,” said John Potthoff, Theorem president and CEO. “He brings expertise in central nervous system, oncology, cardiology, infectious diseases, respiratory and other prime therapeutic areas. We couldn’t have asked for a more perfect fit.”
Treiber, an industry veteran with experience at many of the top global CROs, will oversee all aspects of Theorem’s biopharmaceutical development, including early phase first-in-human and proof-of-concept studies and Phase II-IV studies across a wide range of therapeutic areas.
Before joining Theorem, Treiber held executive-level positions within the CRO and pharma industries. Treiber is a founding member of the Clinical Research Exchange and is active in the Chicagoland Chapter of the Association of Clinical Research Professionals. He earned a bachelor’s in biology from the University of Iowa, a Ph.D. in biology from the University of California, Santa Cruz, and an MBA from Ellis College at the New York Institute of Technology.
About Theorem Clinical Research
Theorem Clinical Research Inc. is a global provider of comprehensive clinical services with staff throughout the Americas, Europe and Asia-Pacific and a client base comprised of the world’s leading biopharmaceutical and medical device companies. With industry-leading experts, unparalleled therapeutic expertise and innovative, groundbreaking technology, Theorem is focused on analytic-based development, combination trials and personal data applications to simplify complex trials.